TearSolutions, Inc., a company spun out of NEI-supported research from the Laurie lab in Cell Biology, just closed its Series B funding of $8.5M. This support was needed to carry the company forward through its current phase 2 trial of ‘Lacripep’ in 201 primary Sjogren’s Syndrome dry eye patients at 27 sites nationwide. If of interest click here.
Follow trial progress here.
The Executive Chairman and Cofounder of TearSolutions is Charlottesville’s Mark Logan, former Chairman, CEO and President of VISX, Inc (invented, obtained FDA approval and commercialized LASIK). TearSolutions President/CEO is Tom Gadek, PhD, a Berkeley chemist who invented the dry eye drug now known as Xiidra. Other members of TearSolutions information here.